Mereo BioPharma Group plc – ADR (MREO) – This company strives to “improve the lives of patients with rare diseases and cancer. They fund and develop high-potential novel therapies that weren’t progressing in pharmaceutical companies; including three product candidates from Novartis and a fourth from AstraZeneca. Since its merger with OncoMed, they have strengthened its balance sheet, broadened its shareholder base, and diversified its product portfolio.
This penny stock has been near $6 in the past. This is a good time to invest – they have delivered three successful Phase 2 studies with a Phase 2 and Phase 1b/2 ongoing. They also have two partnering opportunities that they are exploring.
Learn more at http://www.mereobiopharma.com.